289 related articles for article (PubMed ID: 31914692)
1. Subcellular trafficking of tubular MDM2 implicates in acute kidney injury to chronic kidney disease transition during multiple low-dose cisplatin exposure.
Su H; Ye C; Lei CT; Tang H; Zeng JY; Yi F; Zhang C
FASEB J; 2020 Jan; 34(1):1620-1636. PubMed ID: 31914692
[TBL] [Abstract][Full Text] [Related]
2. MDM2 (murine double minute-2) links inflammation and tubular cell healing during acute kidney injury in mice.
Mulay SR; Thomasova D; Ryu M; Anders HJ
Kidney Int; 2012 Jun; 81(12):1199-211. PubMed ID: 22297670
[TBL] [Abstract][Full Text] [Related]
3. N-acetylcysteine ameliorates cisplatin-induced renal senescence and renal interstitial fibrosis through sirtuin1 activation and p53 deacetylation.
Li C; Xie N; Li Y; Liu C; Hou FF; Wang J
Free Radic Biol Med; 2019 Jan; 130():512-527. PubMed ID: 30447351
[TBL] [Abstract][Full Text] [Related]
4. Integrin β8 prevents pericyte-myofibroblast transition and renal fibrosis through inhibiting the TGF-β1/TGFBR1/Smad3 pathway in diabetic kidney disease.
Cao Y; Su H; Zeng J; Xie Y; Liu Z; Liu F; Qiu Y; Yi F; Lin J; Hammes HP; Zhang C
Transl Res; 2024 Mar; 265():36-50. PubMed ID: 37931653
[TBL] [Abstract][Full Text] [Related]
5. cMet agonistic antibody prevents acute kidney injury to chronic kidney disease transition by suppressing Smurf1 and activating Smad7.
Li L; Lee J; Cho A; Kim JH; Ju W; An JN; Park JH; Zhu SM; Lee J; Yu SS; Lim CS; Kim DK; Kim YS; Yang SH; Lee JP
Clin Sci (Lond); 2021 Jun; 135(11):1427-1444. PubMed ID: 34061176
[TBL] [Abstract][Full Text] [Related]
6. Effects of repeated increasing doses of cisplatin as models of acute kidney injury and chronic kidney disease in rats.
Al Za'abi M; Al Salam S; Al Suleimani Y; Ashique M; Manoj P; Nemmar A; Ali BH
Naunyn Schmiedebergs Arch Pharmacol; 2021 Feb; 394(2):249-259. PubMed ID: 32936352
[TBL] [Abstract][Full Text] [Related]
7. MDM2 mediates fibroblast activation and renal tubulointerstitial fibrosis via a p53-independent pathway.
Ye C; Tang H; Zhao Z; Lei CT; You CQ; Zhang J; Gao P; He FF; Chen S; Wang YM; Zhang C; Su H
Am J Physiol Renal Physiol; 2017 Apr; 312(4):F760-F768. PubMed ID: 28100501
[TBL] [Abstract][Full Text] [Related]
8. Acute Kidney Injury: Tubular Markers and Risk for Chronic Kidney Disease and End-Stage Kidney Failure.
Tan HL; Yap JQ; Qian Q
Blood Purif; 2016; 41(1-3):144-50. PubMed ID: 26764483
[TBL] [Abstract][Full Text] [Related]
9. KLF4 initiates sustained YAP activation to promote renal fibrosis in mice after ischemia-reperfusion kidney injury.
Xu D; Chen PP; Zheng PQ; Yin F; Cheng Q; Zhou ZL; Xie HY; Li JY; Ni JY; Wang YZ; Chen SJ; Zhou L; Wang XX; Liu J; Zhang W; Lu LM
Acta Pharmacol Sin; 2021 Mar; 42(3):436-450. PubMed ID: 32647339
[TBL] [Abstract][Full Text] [Related]
10. Proximal Tubular
Zhang C; Zheng Z; Xu K; Cheng G; Wu H; Liu J
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894939
[TBL] [Abstract][Full Text] [Related]
11. Lethal (3) malignant brain tumor-like 2 (L3MBTL2) protein protects against kidney injury by inhibiting the DNA damage-p53-apoptosis pathway in renal tubular cells.
Huang H; Xu C; Wang Y; Meng C; Liu W; Zhao Y; Huang XR; You W; Feng B; Zheng ZH; Huang Y; Lan HY; Qin J; Xia Y
Kidney Int; 2018 Apr; 93(4):855-870. PubMed ID: 29276099
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of SIRT2 Alleviates Fibroblast Activation and Renal Tubulointerstitial Fibrosis via MDM2.
He FF; You RY; Ye C; Lei CT; Tang H; Su H; Zhang C
Cell Physiol Biochem; 2018; 46(2):451-460. PubMed ID: 29614506
[TBL] [Abstract][Full Text] [Related]
13. Targeting Oct2 and P53: Formononetin prevents cisplatin-induced acute kidney injury.
Huang D; Wang C; Duan Y; Meng Q; Liu Z; Huo X; Sun H; Ma X; Liu K
Toxicol Appl Pharmacol; 2017 Jul; 326():15-24. PubMed ID: 28414026
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of tumor suppressor p53 in acute and chronic kidney diseases.
Overstreet JM; Gifford CC; Tang J; Higgins PJ; Samarakoon R
Cell Mol Life Sci; 2022 Aug; 79(9):474. PubMed ID: 35941392
[TBL] [Abstract][Full Text] [Related]
15. GSK3β-mediated Keap1-independent regulation of Nrf2 antioxidant response: A molecular rheostat of acute kidney injury to chronic kidney disease transition.
Lu M; Wang P; Qiao Y; Jiang C; Ge Y; Flickinger B; Malhotra DK; Dworkin LD; Liu Z; Gong R
Redox Biol; 2019 Sep; 26():101275. PubMed ID: 31349118
[TBL] [Abstract][Full Text] [Related]
16. Sirt6 attenuates hypoxia-induced tubular epithelial cell injury via targeting G2/M phase arrest.
Gao Z; Chen X; Fan Y; Zhu K; Shi M; Ding G
J Cell Physiol; 2020 Apr; 235(4):3463-3473. PubMed ID: 31603249
[TBL] [Abstract][Full Text] [Related]
17. MDM2 prevents spontaneous tubular epithelial cell death and acute kidney injury.
Thomasova D; Ebrahim M; Fleckinger K; Li M; Molnar J; Popper B; Liapis H; Kotb AM; Siegerist F; Endlich N; Anders HJ
Cell Death Dis; 2016 Nov; 7(11):e2482. PubMed ID: 27882940
[TBL] [Abstract][Full Text] [Related]
18. N-acetyl-cysteine increases cellular dysfunction in progressive chronic kidney damage after acute kidney injury by dampening endogenous antioxidant responses.
Small DM; Sanchez WY; Roy SF; Morais C; Brooks HL; Coombes JS; Johnson DW; Gobe GC
Am J Physiol Renal Physiol; 2018 May; 314(5):F956-F968. PubMed ID: 29357409
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin nephrotoxicity as a model of chronic kidney disease.
Shi M; McMillan KL; Wu J; Gillings N; Flores B; Moe OW; Hu MC
Lab Invest; 2018 Aug; 98(8):1105-1121. PubMed ID: 29858580
[TBL] [Abstract][Full Text] [Related]
20. Phlda3, a urine-detectable protein, causes p53 accumulation in renal tubular cells injured by cisplatin.
Lee CG; Kang YJ; Kim HS; Moon A; Kim SG
Cell Biol Toxicol; 2015 Apr; 31(2):121-30. PubMed ID: 25809501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
